mycophenolic-acid and Lymphoma--Follicular

mycophenolic-acid has been researched along with Lymphoma--Follicular* in 2 studies

Trials

1 trial(s) available for mycophenolic-acid and Lymphoma--Follicular

ArticleYear
Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:2

    Nonmyeloablative hematopoietic cell transplantation (HCT) has been used to treat patients with advanced or high-risk lymphoid malignancies. We studied 65 patients (median age 46 years) receiving an umbilical cord blood (UCB) graft after a single conditioning regimen consisting of cyclophosphamide (50 mg/kg) on day -6, fludarabine (40 mg/m(2)) daily on days -6 to -2, as well as a single fraction of total-body irradiation (TBI) (200 cGy) along with cyclosporine mycophenolate mofetil immunosuppression. Median time to neutrophil and platelet recovery was 7.5 days (range: 0-32) and 46 days (range: 8-111), respectively. Cumulative incidences of grade II-IV, grade III-IV acute, and chronic graft-versus-host disease (aGVHD, cGVHD) were 57% (95% confidence interval [CI]: 43%-70%), 25% (95% CI: 14%-35%), and 19% (95% CI: 9%-29%), respectively. Transplant-related mortality at 3 years was 15% (95% CI: 5%-26%). Median follow-up was 23 months. The progression free-survival (PFS), current PFS and overall survival (OS) were 34% (95% CI: 21%-47%), 49% (95% CI: 36%-62%), and 55% (95% CI: 42%-70%) at 3 years. Based on our data, we conclude that a nonmyeloablative conditioning regimen followed by UCB transplantation is an effective treatment for patients with advanced lymphoid malignancies who lack a suitable sibling donor.

    Topics: Adolescent; Adult; Aged; Child; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Humans; Immunosuppression Therapy; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mycophenolic Acid; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2009

Other Studies

1 other study(ies) available for mycophenolic-acid and Lymphoma--Follicular

ArticleYear
Calcineurin inhibitor-free GVHD prophylaxis with sirolimus and mycophenolate mofetil combination.
    Annals of hematology, 2017, Volume: 96, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Middle Aged; Mycophenolic Acid; Myelodysplastic Syndromes; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Sirolimus

2017